Literature DB >> 15768345

Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.

Alain H Litwin1, Irene Soloway, Marc N Gourevitch.   

Abstract

Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy. The most significant barrier to treatment is lack of access to comprehensive HCV-related care. We describe a pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone. This on-site, multidisciplinary model of care includes comprehensive screening and treatment for HCV infection, assessment of eligibility, counseling with regard to substance abuse, psychiatric services, HCV support groups, directly observed therapy, and enhanced linkages to a tertiary care system for diagnostic procedures. Our approach has led to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Two cases illustrate the successful application of this model to patients with HCV infection complicated by active substance abuse and psychiatric comorbidity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768345     DOI: 10.1086/427450

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

2.  Integrating hepatitis services into substance abuse treatment programs: new initiatives from SAMHSA.

Authors:  Thomas F Kresina; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

3.  Can urban methadone patients complete health utility assessments?

Authors:  Paul A Teixeira; Bruce R Schackman
Journal:  Patient Educ Couns       Date:  2008-03-07

4.  Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program.

Authors:  Robert J Roose; Lauren Cockerham-Colas; Irene Soloway; Abigail Batchelder; Alain H Litwin
Journal:  J Health Care Poor Underserved       Date:  2014-05

5.  Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level.

Authors:  Arlene C Seña; Sarah J Willis; Alison Hilton; Alexandria Anderson; David A Wohl; Christopher B Hurt; Andrew J Muir
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

6.  Strategies used by people who inject drugs to avoid stigma in healthcare settings.

Authors:  Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi
Journal:  Drug Alcohol Depend       Date:  2019-03-08       Impact factor: 4.492

Review 7.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

8.  Managing Hepatitis C in Users of Illicit Drugs.

Authors:  Brian R Edlin; Michael R Carden; Stephen J Ferrando
Journal:  Curr Hepat Rep       Date:  2007

9.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

10.  Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.

Authors:  Imke Schreuder; Marianne Ab van der Sande; Matty de Wit; Monique Bongaerts; Charles Ab Boucher; Esther A Croes; Maaike G van Veen
Journal:  Harm Reduct J       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.